What type of study is this?

This is a Cohort Study study (also classified as: Human Clinical Trial).

December 8, 2025Blood

A prospective Study of whole genome sequencing for genomic profiling and risk determination in MDS

View Full Paper

Ask AI

Bookmark

Authors

Prospective trial demonstrates whole genome sequencing enhances genomic profiling in myeloid malignancies, indicating improved risk prediction.

Whole genome sequencing revealed new genomic information that altered risk category in 15% of patients with myeloid malignancies.
WGS demonstrated success in 100% of cases, contrasting with conventional cytogenetics failures in 14% of patients enrolled.
Assessment employed WGS targeting small variants, copy-number alterations, and structural variants in recurrent myeloid genes.
Improved risk stratification through whole genome sequencing supports its utility as an optimal assay for myeloid malignancy management.

Jesus et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Prospective trial demonstrates whole genome sequencing enhances genomic profiling in myeloid malignancies, indicating improved risk prediction.

Whole genome sequencing revealed new genomic information that altered risk category in 15% of patients with myeloid malignancies.
WGS demonstrated success in 100% of cases, contrasting with conventional cytogenetics failures in 14% of patients enrolled.
Assessment employed WGS targeting small variants, copy-number alterations, and structural variants in recurrent myeloid genes.
Improved risk stratification through whole genome sequencing supports its utility as an optimal assay for myeloid malignancy management.

Jesus et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark